Loading...

Vaxxinity, Inc.

VAXX•NASDAQ
Healthcare
Biotechnology
$0.02
$-0.01(-33.33%)

Vaxxinity, Inc. (VAXX) Stock Overview

Explore Vaxxinity, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.6/100

Key Financials

Market Cap1.1B
P/E Ratio-0.04
EPS (TTM)$-0.45
ROE-0.00%
Fundamental Analysis

AI Price Forecasts

1 Week$0.01
1 Month$0.25
3 Months$0.20
1 Year Target$0.00

VAXX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Vaxxinity, Inc. (VAXX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 50.70, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.04 and a market capitalization of 1.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

50.70RSI (14)
0.01MACD
15.36ADX
Stats data is not available for VAXXStats details for VAXX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for VAXXAnalyst Recommendations details for VAXX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

CEO

Mei Mei Hu

Employees

57

Headquarters

1717 Main Street, Dallas, TX

Founded

2021

Frequently Asked Questions

;